By Trevor Hunnicutt BALTIMORE (Reuters) -U.S. President Joe Biden said on Wednesday that other pharmaceutical companies will have to lower their insulin prices in the wake of Eli Lilly’s decisio[...]
Read more
Health
US panel backs GSK vaccine, heating up RSV vaccine race
By Khushi Mandowara and Mariam ESunny (Reuters) -A panel of outside advisers to the U.S. health regulator on Wednesday backed GSK Plc’s respiratory syncytial virus (RSV) vaccine, setting it up f[...]
Read more
Lilly to cut some list prices by 70% and offer $25 insulin
By Bhanvi Satija and Patrick Wingrove (Reuters) -Eli Lilly and Co on Wednesday said it will cut list prices by 70% for its most commonly prescribed insulin products, Humalog and Humulin, beginning fro[...]
Read more
Bayer braces for falling profits in challenge for new CEO
By Ludwig Burger FRANKFURT (Reuters) -Bayer warned operating earnings would decline in 2023, adding to the challenges for its new CEO who will take the helm in June, as the agriculture and healthcare[...]
Read more
U.S. Commerce to ask companies seeking chips funding to provide childcare for employees
By David Shepardson WASHINGTON (Reuters) -The U.S. Commerce Department said on Monday it plans to ask companies seeking at least $150 million in funding from a $52 billion semiconductor law to submit[...]
Read more
US 2022 power plant emissions fell on switch from coal to gas -EPA
By Timothy Gardner WASHINGTON (Reuters) – U.S. power plant emissions of pollutants that harm human health and warm the planet fell last year as the industry continued a switch from coal to natur[...]
Read more
Pfizer in talks to buy cancer drugmaker Seagen – WSJ
(Reuters) -Pfizer Inc is in early-stage talks to acquire cancer drugmaker Seagen Inc in a potential multi-billion dollar deal, the Wall Street Journal reported, after advanced discussions between Merc[...]
Read more
Nissan raises global EV targets; to boost U.S. input
TOKYO (Reuters) -Nissan Motor Co Ltd on Monday raised its electrified car sales goals and said it would boost power train production in the United States, as it looks to catch up in a segment dominate[...]
Read more
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval
By Rocky Swift TOKYO (Reuters) – Japan’s Shionogi & Co Ltd believes its COVID-19 pill will easily garner $2 billion in annual sales if it secures U.S. approval, which the company expec[...]
Read more